Longeveron LLC (LGVN) - Total Assets
Based on the latest financial reports, Longeveron LLC (LGVN) holds total assets worth $15.49 Million USD as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Longeveron LLC - Total Assets Trend (2018–2025)
This chart illustrates how Longeveron LLC's total assets have evolved over time, based on quarterly financial data. Also see Longeveron LLC stock valuation for the company's overall valuation and market capitalisation.
Longeveron LLC - Asset Composition Analysis
Current Asset Composition (December 2025)
Longeveron LLC's total assets of $15.49 Million consist of 53.1% current assets and 46.9% non-current assets. Review LGVN liabilities breakdown to assess the company's total debt and financial obligations.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 45.4% |
| Accounts Receivable | $104.00K | 1.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $2.29 Million | 22.3% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2018–2025)
This chart illustrates how Longeveron LLC's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See LGVN stock price and chart for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Longeveron LLC's current assets represent 53.1% of total assets in 2025, an increase from 39.6% in 2018.
- Cash Position: Cash and equivalents constituted 45.4% of total assets in 2025, up from 38.3% in 2018.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 22.0% of total assets, an increase from 12.0% in 2018.
- Asset Diversification: The largest asset category is intangible assets at 22.3% of total assets.
Longeveron LLC Competitors by Total Assets
Key competitors of Longeveron LLC based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
ALK-Abelló A/S
CO:ALK-B
|
Denmark | Dkr9.17 Billion |
|
Mirum Pharmaceuticals Inc
NASDAQ:MIRM
|
USA | $890.92 Million |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278
|
China | CN¥3.21 Billion |
|
BB Biotech AG
SW:BION
|
Switzerland | CHF3.09 Billion |
|
Soleno Therapeutics Inc
NASDAQ:SLNO
|
USA | $608.39 Million |
|
Nanobiotix
NASDAQ:NBTX
|
USA | $67.76 Million |
|
Inhibrx Biosciences, Inc.
NASDAQ:INBX
|
USA | $183.97 Million |
|
Wuhan Keqian Biology Co Ltd
SHG:688526
|
China | CN¥4.75 Billion |
Longeveron LLC - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.63 | 3.43 | 10.18 |
| Quick Ratio | 2.63 | 3.43 | 10.18 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $7.02 Million | $7.99 Million | $17.73 Million |
Longeveron LLC - Advanced Valuation Insights
This section examines the relationship between Longeveron LLC's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.45 |
| Latest Market Cap to Assets Ratio | 2.30 |
| Asset Growth Rate (YoY) | -59.9% |
| Total Assets | $10.26 Million |
| Market Capitalization | $23.60 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Longeveron LLC's assets at a significant premium (2.30x), suggesting investors see substantial growth potential or unique competitive advantages.
Significant Asset Reduction: Longeveron LLC's assets decreased by 59.9% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Longeveron LLC (2018–2025)
The table below shows the annual total assets of Longeveron LLC from 2018 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $10.26 Million | -59.85% |
| 2024-12-31 | $25.56 Million | +111.61% |
| 2023-12-31 | $12.08 Million | -55.94% |
| 2022-12-31 | $27.41 Million | -35.90% |
| 2021-12-31 | $42.77 Million | +362.84% |
| 2020-12-31 | $9.24 Million | -12.70% |
| 2019-12-31 | $10.58 Million | +0.60% |
| 2018-12-31 | $10.52 Million | -- |
About Longeveron LLC
Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States. Its lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young and healthy adult donors which is in phase 3 clinical trial to treat hypoplastic left heart syndrome; com… Read more